#POLB Poolbeg Pharma PLC – Director/PDMR Shareholding June 25, 2025 – Posted in: Poolbeg Pharma (POLB)

25 June 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, confirms that as announced on 20 May 2025, Mr Cathal Friel, Executive Chair and PDMR of the Company, participated in the Fundraising subscribing for 4,000,000 new Ordinary Shares at a price of 2.5p per share (the Issue Price). Following the AGM earlier this week, the New Ordinary Shares issued pursuant…

#POLB Poolbeg Pharma PLC – Combination of Poolbeg and HOOKIPA Pharma Inc. January 2, 2025 – Posted in: Blog

The boards of directors (each a “Board”) of HOOKIPA Pharma Inc. (“HOOKIPA”) and Poolbeg Pharma plc (“Poolbeg”) are pleased to announce that they have entered into non-binding discussions for an all-share acquisition by HOOKIPA of Poolbeg (the “Potential Combination”) to create a strong clinical-stage biopharmaceutical company focused on developing and commercialising innovative medicines for critical unmet medical needs, with a special focus on next-generation immunotherapies for the treatment of cancer and other serious diseases (the…

#POLB Poolbeg Pharma PLC – POLB 001 data to be presented at ASH November 6, 2024 – Posted in: Poolbeg Pharma (POLB)

6 November 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, today announces that it will present a poster detailing POLB 001’s efficacy in reducing immunotherapy-induced CRS in an in vivo animal model, at the 66th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, taking place 7-10 December 2024 in San Diego, California. Poolbeg’s poster presentation will provide insights into the results…

#POLB Poolbeg Pharma PLC – H.C. Wainwright Global Investment Conference August 27, 2024 – Posted in: Poolbeg Pharma (POLB)

27 August 2024 - Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that Jeremy Skillington, PhD, Chief Executive Officer and David Allmond, Chief Business Officer will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference, being held on 9-11 September 2024 in New York and virtually. The presentation will be available to view…

#POLB Poolbeg Pharma PLC – Voluntary Delisting from OTCQB Market July 26, 2024 – Posted in: Poolbeg Pharma (POLB)

26 July 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it is voluntarily delisting its ordinary shares (“Ordinary Shares”) from trading on the OTCQB Market due to low trading volume and the associated administrative requirements. The Company’s last day of trading on the OTCQB Market will be Monday 29 July 2024. Poolbeg…

#POLB Poolbeg Pharma PLC – Annual Report & AGM Notice May 9, 2024 – Posted in: Poolbeg Pharma (POLB)

9 May 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, confirms that the Company’s Annual Report and Accounts for the period ended 31 December 2023 and the notice of Annual General Meeting (“AGM”) will be posted to shareholders today. The 2023 Annual Report and Accounts, the Notice of AGM and accompanying form of…

#POLB Poolbeg Pharma PLC – Board Role Change and Launch of EIP February 15, 2024 – Posted in: Blog, Poolbeg Pharma (POLB)

15 February 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, “Poolbeg” or the “Company”), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change of Board role and the Remuneration Committee’s approval of the adoption of an Employee Performance Incentive Plan (“EIP”) for a number of the key senior management, to align medium and long term objectives with those of shareholders and to encourage…

#POLB Poolbeg Pharma PLC – RSV AI Drug Candidate Analysis Update December 20, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces the positive outputs from the lab-based analysis and successful prioritisation of the Respiratory Syncytial Virus (‘RSV’) drug targets and treatments identified as part of its artificial intelligence (‘AI’) led programme. Poolbeg’s team of scientific experts have reviewed the comprehensive data package obtained from this lab-based…

#POLB Poolbeg Pharma PLC – Directorate Change November 30, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

30 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change to its Board of Directors. Patrick Ashe, Independent Non-Executive Director, will step down from the Board at the end of November. Eddie Gibson, Non-Executive Director will replace Patrick as Chair of the Audit & Risk Committee and Prof Brendan Buckley, Non-Executive Director…

#POLB Poolbeg Pharma PLC – POLB 001 LPS Trial Data to be Presented at IUIS November 16, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

16 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted for presentation at the 18th International Congress of Immunology (‘IUIS’), to be held 27 November – 2 December 2023 in Cape Town, South Africa. IUIS is the world’s…